Dr. Claassen is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3601 21st Ave S
Nashville, TN 37232Phone+1 615-322-3000Fax+1 615-936-0605
Summary
- Dr. Daniel Claassen, based in Nashville, TN, is a neurologist specializing in neurophysiology and movement disorders. He completed his medical education at the Medical College of Georgia at Augusta University in 2005 and received his post-doctoral training in neurodegenerative disorders at the University of Virginia Medical Center between 2009 and 2011. His residency and internship in internal medicine were pursued at the Mayo Clinic College of Medicine and Science. He has contributed to multiple publications, appearing in notable journals such as the New England Journal of Medicine and the European Journal of Neuroscience. Dr. Claassen is experienced in conducting clinical trials and is currently engaged in studies on autonomic failure and Progressive Supranuclear Palsy.
Education & Training
University of Virginia Medical CenterPost-Doctoral Fellowship, 2009 - 2011
Mayo Clinic College of Medicine and Science (Rochester)Residency, Neurology, 2006 - 2009- Mayo Clinic College of Medicine and Science (Rochester)Internship, Internal Medicine, 2005 - 2006
Medical College of Georgia at Augusta UniversityClass of 2005
Certifications & Licensure
TN State Medical License 2011 - 2026
VA State Medical License 2009 - 2012
FL State Medical License 2008 - 2010
MN State Medical License 2006 - 2009
WI State Medical License 2008 - 2009- American Board of Psychiatry and Neurology Neurology
- United Council for Neurologic SubspecialtiesBehavioral Neurology & Neuropsychiatry
Clinical Trials
- Safety, Tolerability, and Pharmacokinetics of C2N-8E12 in Subjects With Progressive Supranuclear Palsy Start of enrollment: 2015 Jul 01
- [18F]F-DOPA Imaging in Patients With Autonomic Failure Start of enrollment: 2020 Feb 04
Publications & Presentations
PubMed
- Correction: Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia and Chorea Associated with Huntington Disease.Samuel Frank, Karen E Anderson, Hubert H Fernandez, Robert A Hauser, Daniel O Claassen
Neurology and Therapy. 2024-12-01 - Apathy and Functional Status in Early-Stage Huntington's Disease.Jessie S Gibson, Kaitlyn R Hay, Daniel O Claassen, Katherine E McDonell, Amy E Brown
The Journal of Neuropsychiatry and Clinical Neurosciences. 2024-11-19 - Guidance on antipsychotic selection for agitation and aggressive behavior in persons with Huntington's disease.James E Eaton, Daniel O Claassen
Expert Review of Neurotherapeutics. 2024-10-01
Press Mentions
Alterity Therapeutics Announces Presentation of MRI Data from the bioMUSE Natural History Study at the American Neurological Association Annual MeetingOctober 26th, 2022- Alterity Therapeutics Announces Presentation of MRI Data from the bioMUSE Natural History Study at the American Neurological Association Annual MeetingOctober 26th, 2022
- With Huntington’s Disease, Renewed Hope for a Cure Draws More Interest in Testing at VanderbiltAugust 15th, 2022
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
